Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo to Streamline Vaccine Business in April 2019, Setting Up New Manufacturing Company
May 7, 2018
- Japan to Join Jardiance Study for CKD under Collaboration between Boehringer, Lilly, and Oxford
May 2, 2018
- Takeda’s Takeover Bid for Shire “Thought-Provoking”: Daiichi Sankyo CEO
May 1, 2018
- Despite Upbeat AGs, Daiichi Sankyo to Closely Watch Pricing Environment: CEO
May 1, 2018
- Daiichi Sankyo to Announce “Important Measures” to Shore Up Biz by 2nd Qtr Earnings
May 1, 2018
- Olmetec Sales Nosedive 67.8% in North America in FY2017: Daiichi Sankyo
May 1, 2018
- Keytruda-Chemo Combo Filed for NSCLC without PD-L1 Cutoff
May 1, 2018
- Sumitomo Dainippon Slashes FY2017 Profit Outlook
April 27, 2018
- Boehringer Ingelheim Japan Sees 10% Dip in Pharma Sales as Micardis LOE Weighs
April 27, 2018
- Astellas Vows Intensive Investment in 6 Late-Stage Assets to Weather Patent Cliff: CEO
April 27, 2018
- Torii Calls Off PII Study of Menlo’s Pruritus Candidate
April 27, 2018
- Ono Files Metyrosine in Japan
April 27, 2018
- Chugai Seeks Japan OK for Hemlibra in Non-Inhibitor Carriers, New Dosing
April 27, 2018
- Bayer Japan Chief “Disappointed” at PMP Removal for Xarelto, Shows Eagerness for Add’l Indications
April 27, 2018
- Astellas Sales Drop 0.9% due to LLP Sell-Off, Japan Biz Hit by Generic Entry
April 27, 2018
- Otsuka’s Jynarque Earns FDA Nod for ADPKD at Second Attempt
April 26, 2018
- Encorafenib/Binimetinib Combo Filed in Japan: Ono
April 26, 2018
- Jitsubo Aims to Enter Contract-Manufacturing Business for Peptide Drug Substances
April 25, 2018
- Gilteritinib Filed in Japan, US for AML: Astellas
April 25, 2018
- Takeda, Shire Reach Preliminary Deal, Extend Takeover Deadline to May 8
April 25, 2018
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…